September 27, 2022
Life Sciences
  • Pfizer announced it asked the Food and Drug Administration (FDA) to approve its omicron-specific COVID-19 booster shot for children between the ages of 5 and 11. Pfizer asked the FDA to authorize a 10-microgram dose for children, one-third of the 30 microgram dose that was authorized for adults in August. Pfizer said its decision to request authorization was supported by “safety and immunogenicity data” as well as “non-clinical” and “pre-clinical” data. (Articles here, here, here, and here)